Academic Background

BSc in microbiology (Hons) University of Bristol (1980), PhD in viral-immunology, University of London (1985). Postdoctoral fellow University College Medical School London, and Howard Hughes Medical Institute, Columbia University, New York (1985-1992). Director of research, Centre d'Immunology, Marseille (1992-1999). Senior Lecturer then Reader, Imperial College London (1999-2003). Lecturer then titular Reader then titular Professor, The Sir William Dunn School of Pathology, University of Oxford (2003-present).

Undergraduate Teaching

- Lectures: undergraduate medicine BM part 2 and FHS; biochemistry FHS; MSc in Immunology. - Practical demonstration: undergraduate medicine BM part 2. - Tutorials: undegraduate medicine BM parts 1 and 2 and FHS; physiological sciences all years; graduate entry medicine year 1; biochemistry years 2 and 3.

Research Interests

The cellular and molecular biology of human immunodeficiency virus type-1 (HIV-1) dissemination. Design of vaccines to elicit systemic and mucosal neutralising antibodies to HIV-1. Characterising the role of reactive carbonyls in immune hypersensitivity, allergy and autoimmunity.

Selected Publications

Sattentau QJ. (2008). Avoiding the void: cell-to-cell spread of human viruses. Nature Reviews Microbiology 6:815-26.

Groot F, Welsch S and Sattentau QJ. (2008). Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111: 4660-4663.

Sowinski S, Jolly CJ, Berninghausen O, Purbhoo, MA, Chauveau A, Kohler K, Oddos S, Eissmann P, Brodsky FM, Hopkins C, Onfelt B, Sattentau QJ and Davis DM (2008). Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nature Cell. Biol. 10: 211-219.

Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ* and Openshaw PJM* (2006). *equal contribution. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nature Medicine 12: 905-907.

Jolly, C, Kashefi, K, Hollinshead, M and Sattentau, QJ (2004) HIV-1 cell-to-cell transfer across an Env-induced, actin-dependent synapse. J. Exp Med. 199: 283-193.

Pinon, J.D., Klasse, P-J., Jassal, S.R., Welson, S., Weber, J.N., Brighty, D.W., Sattentau, Q.J. (2003). Human T cell leukemia virus type-1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J. Virol. 77: 9922-9930.

Moulard, M., Lortat-Jacob, H., Mondor, I., Roca, G., Wyatt, R., Sodroski, J., Maddon, P., Olson, W., Kwong, P. and Sattentau, Q.J. (2000) Selective polyanion interactions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:1948-1960.

Ugolini, S., Mondor, I., Parren, P. W. H. I., Burton, D., Tilley, S., Klasse, PJ, Sattentau, Q.J. (1997). Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J. Exp. Med. 186: 1287-1298.

Parren, P. I., Burton, D. and Sattentau, Q.J. (1997). The antibody response to HIV-1 envelope may be primarily elicited by viral debris and not the virus. Nature Medicine 3: 366-368.

Poignard, P., Fouts, T., Naniche, D., Moore, J.P., and Sattentau, Q.J. (1996). Neutralizing antibodies to human immunodeficiency virus type 1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 183: 473-484.

Sattentau, Q.J., and Moore, J.P. (1995). Human immunodeficiency virus type-1 neutralization is determined by epitope exposure on the glycoprotein gp120 oligomer. J. Exp. Med. 182: 185-196.

Sattentau, Q.J. and Moore, J.P. (1991). Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174: 407-415.